11 new oncology trials approved in Europe
 |
Oncology Hero |
11 new oncology trials approved in Europe
Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe.
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1)
| Sponsor: Eli Lilly & Co. | Phase: |
Interested in offering this trial to suitable patients?
Register Investigator InterestA multicentre open-label phase I/Ib trial of melanoma-specific peptide vaccination (UniCanVax) combined with nivolumab in checkpoint blockade-refractory stage III/IV melanoma
| Sponsor: Humanitas Mirasole S.p.A. | Phase: 1 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 2, Randomized, Open-label Study of VVD-133214 with Pembrolizumab versus Pembrolizumab Monotherapy in Advanced MSI-H/dMMR Colorectal Adenocarcinoma
| Sponsor: Vividion Therapeutics Inc. | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestUse of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients (ALPACA)
| Sponsor: Institute Of Oncology Ljubljana | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestORION-1: A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-023 as a single agent, and in combination with AVZO-021 and/or endocrine therapy in patients with advanced solid tumors
| Sponsor: Avenzo Therapeutics Inc. | Phase: 1, 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestSAKK 18/25 (ORIGIN2): Gemcitabine plus Ivonescimab in Advanced NSCLC Progressing on Immune Checkpoint Inhibitors
| Sponsor: Swiss Cancer Institute | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestDiagnostic Performance of [68Ga]Ga-HKG301 (FAP-2286) PET/CT in Biologic Borderline Resectable Pancreatic and Invasive Lobular Breast Cancers – FAPTRACE Trial
| Sponsor: Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestMulticenter, Open-label, Randomized Phase 2 Study of Weekly versus Alternative Ficerafusp Alfa Dosing in Combination with Pembrolizumab for First-line Recurrent or Metastatic HNSCC
| Sponsor: Bicara Therapeutics Inc. | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA clinical trial of MK-1568 in participants with prostate cancer (MK-1568-001)
| Sponsor: Merck Sharp & Dohme LLC | Phase: 1 |
Interested in offering this trial to suitable patients?
Register Investigator InterestPPPTH: Phase II Randomized Trial of Topical Papaverine to Prevent Postoperative Hypoparathyroidism After Total Thyroidectomy
| Sponsor: Azienda Provinciale Per I Servizi Sanitari | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestVIVALDI: A Pilot Study of the LSD1 Inhibitor Iadademstat in Combination with Azacitidine and Venetoclax in Newly Diagnosed Acute Myelogenous Leukemia Patients with Suboptimal Response to the Standard of Care Treatment.
| Sponsor: Grupo Cooperativo De Estudio Y Tratamiento De Las Leucemias Agudas Y Mielodisplasias | Phase: |
Interested in offering this trial to suitable patients?
Register Investigator InterestOncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Oncology Hero
Sharing the latest updates in oncology
Oncology Hero 9 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe. VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib with Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer Sponsor: Celcuity Inc. Phase: 3 Interested in offering...
Oncology Hero 12 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe. EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC. Sponsor: European Organisation For Research And Treatment Of Cancer Phase:...
Oncology Hero 11 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients Sponsor: Centre Leon Berard Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest PD-1 blockade alone versus...